We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Bio-Rad Laboratories, Inc. (BIO - Free Report) is slated to report third-quarter 2020 results on Oct 29, after the closing bell.
In the last-reported quarter, the company’s earnings per share (EPS) of $1.91 surpassed the Zacks Consensus Estimate by 23.9%. Moreover, its earnings surpassed the consensus estimate in three of the last four quarters and lagged in one. The trailing four-quarter average surprise is 18.2%.
Factors at Play
According to Bio-Rad’s last update, its manufacturing operations team has responded to the pandemic strategically. Although in the initial phase of the pandemic, the company experienced some supply chain disruptions, since the middle of the second quarter, it has ramped up production to meet increased demand of mainly its PCR instruments and reagents. This uptrend is expected to be reflected in the company’s third-quarter results.
Further, as confirmed during the second-quarter earnings call, the pandemic resulted in a pronounced change in product demand across the company’s portfolio. While the company recorded strong orders for Polymerase Chain Reaction (PCR)-based products related to COVID-19 testing and research, lower demand resulted mainly within the clinical diagnostics portfolio due to widespread lockdowns. This trend is likely to have continued in the third quarter leading to strong sales particularly within core PCR products, Droplet Digital PCR and Process Media.
Bio-Rad, in April, launched SARS-CoV-2 Total Ab test, which is a blood-based immunoassay kit to help determine if an individual has developed antibodies to SARS-CoV-2, the virus causing COVID-19. Notably, this test got both the FDA’s Emergency Use Authorization (EUA) and CE Mark approval. The company has been ramping up its production to meet surging demand globally. This is likely to have significantly boosted the company’s third-quarter top line.
The company also received another EUA in May for its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit. Bio-Rad, which is already riding on robust demand for its PCR and ddPCR products, is likely to have been benefited from the launch of the test kit in the third quarter.
However, academic research labs around the globe are currently operating materially below capacity. This might have impacted the company’s third-quarter top line. Clinical Diagnostics segment too is expected to have experienced weakness across all its product lines due to reduced demand from lower noncritical hospital and clinic visits.
Q3 Estimates
The Zacks Consensus Estimate for third-quarter 2020 revenues is pegged at $565.3 million, suggesting a 0.8% rise from the year-ago figure.
The Zacks Consensus Estimate for the company’s EPS of $1.85 suggests an improvement of 14.9% from the year-ago figure.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has good chances of beating estimates. However, this is not the case here as you can see:
Earnings ESP: Bio-Rad has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
Humana (HUM - Free Report) currently has a Zacks Rank #2 and an Earnings ESP of +3.35%.
LHC Group has an Earnings ESP of +1.85% and a Zacks Rank of 2, at present.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
Bio-Rad Laboratories, Inc. (BIO - Free Report) is slated to report third-quarter 2020 results on Oct 29, after the closing bell.
In the last-reported quarter, the company’s earnings per share (EPS) of $1.91 surpassed the Zacks Consensus Estimate by 23.9%. Moreover, its earnings surpassed the consensus estimate in three of the last four quarters and lagged in one. The trailing four-quarter average surprise is 18.2%.
Factors at Play
According to Bio-Rad’s last update, its manufacturing operations team has responded to the pandemic strategically. Although in the initial phase of the pandemic, the company experienced some supply chain disruptions, since the middle of the second quarter, it has ramped up production to meet increased demand of mainly its PCR instruments and reagents. This uptrend is expected to be reflected in the company’s third-quarter results.
Further, as confirmed during the second-quarter earnings call, the pandemic resulted in a pronounced change in product demand across the company’s portfolio. While the company recorded strong orders for Polymerase Chain Reaction (PCR)-based products related to COVID-19 testing and research, lower demand resulted mainly within the clinical diagnostics portfolio due to widespread lockdowns. This trend is likely to have continued in the third quarter leading to strong sales particularly within core PCR products, Droplet Digital PCR and Process Media.
BioRad Laboratories, Inc. Price and EPS Surprise
BioRad Laboratories, Inc. price-eps-surprise | BioRad Laboratories, Inc. Quote
Bio-Rad, in April, launched SARS-CoV-2 Total Ab test, which is a blood-based immunoassay kit to help determine if an individual has developed antibodies to SARS-CoV-2, the virus causing COVID-19. Notably, this test got both the FDA’s Emergency Use Authorization (EUA) and CE Mark approval. The company has been ramping up its production to meet surging demand globally. This is likely to have significantly boosted the company’s third-quarter top line.
The company also received another EUA in May for its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit. Bio-Rad, which is already riding on robust demand for its PCR and ddPCR products, is likely to have been benefited from the launch of the test kit in the third quarter.
However, academic research labs around the globe are currently operating materially below capacity. This might have impacted the company’s third-quarter top line. Clinical Diagnostics segment too is expected to have experienced weakness across all its product lines due to reduced demand from lower noncritical hospital and clinic visits.
Q3 Estimates
The Zacks Consensus Estimate for third-quarter 2020 revenues is pegged at $565.3 million, suggesting a 0.8% rise from the year-ago figure.
The Zacks Consensus Estimate for the company’s EPS of $1.85 suggests an improvement of 14.9% from the year-ago figure.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has good chances of beating estimates. However, this is not the case here as you can see:
Earnings ESP: Bio-Rad has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
Humana (HUM - Free Report) currently has a Zacks Rank #2 and an Earnings ESP of +3.35%.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.35% and is a Zacks #2 Ranked stock. You can see the complete list of today’s Zacks #1 Rank stocks here.
LHC Group has an Earnings ESP of +1.85% and a Zacks Rank of 2, at present.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>